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Abstract: Sleep problems are frequently reported in infants treated with propranolol for infantile he-
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this cohort study, we objectively investigate the sleep behavior of infants with infantile hemangiomas on
propranolol compared to a healthy, untreated control group. Sleep of propranolol-treated infants and
controls was investigated using ankle actigraphy and a 24-h diary for 7-10 days at ages 3 and 6 months.
The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main
secondary outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated
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reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment
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Abstract
Sleep problems are frequently reported in infants treated with propranolol for infantile hemangiomas, possibly serving as a
marker for a negative impact on central nervous system function. In this cohort study, we objectively investigate the sleep
behavior of infants with infantile hemangiomas on propranolol compared to a healthy, untreated control group. Sleep of
propranolol-treated infants and controls was investigated using ankle actigraphy and a 24-h diary for 7–10 days at ages 3 and
6 months. The main outcome measures were the Number of Nighttime Awakenings and Sleep Efficiency. The main secondary
outcome measures included 24-hour Total Sleep, daytime sleep behavior, and parent-rated infant sleep quality and behavioral
development based on the Brief Infant Sleep Questionnaire (BISQ) and the age-appropriate Ages-and-Stages Questionnaire
(ASQ), respectively. Fifty-four term-born infants were included in each cohort. No group difference in any investigated param-
eter was seen at age 3 months. At age 6 months, the propranolol group exhibited a decrease in Sleep Efficiency and a trend
towards an increased Number of Nighttime Awakenings compared to the control group. Treated infants at 6 months also had
shorter daytime waking periods. 24-hour Total Sleep was unaffected by propranolol. No negative impact of propranolol on
subjective sleep quality and behavioral development was noted.
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Conclusion: Propranolol exerts a measurable yet mild impact on objectively assessed infants’ sleep measures. Behavioral
developmental scores were unaffected. Our results support propranolol as first-line therapy for complicated infantile
hemangiomas.
What is Known:
• Sleep disorders are frequently reported in infants with infantile hemangiomas treated with propranolol and often lead to treatment discontinuation.
• Investigations of the sleep pattern in this patient group using objective measures are lacking.
What is New:
• The sleep pattern of propranolol-treated infants is assessed using actigraphy and a 24-h sleep diary and compared to healthy, untreated controls.
• Propranolol leads to a decreased sleep efficiency at night and an increased demand of daytime sleep, yet effects are mild overall.
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Abbreviations
IH Infantile hemangioma
BISQ Brief Infant Sleep Questionnaire
ASQ Ages-and-Stages Questionnaire
PSQI Pittsburgh Sleep Quality Index
Introduction
Systemic propranolol is considered first-line treatment
for complicated infantile hemangiomas (IH), given its
excellent efficacy and safety [1, 2]. As a lipophilic mol-
ecule, propranolol can cross the blood-brain barrier,
leading to concerns for a potentially negative impact
on central nervous system (CNS) function [3, 4].
Indeed, parents have reported sleep disturbances such
as insomnia, night restlessness, hypersomnia, and
nightmares/night terrors in up to 30% of treated infants
[2, 5–8]. Intolerable sleep problems are the most fre-
quent reason for early propranolol discontinuation,
which may result in a poorer overall outcome of treated
IH [9].
Sleep fulfills an essential function in development and is
linked to brain maturation, neural reorganization, and process-
es of learning and memory [10, 11]. While available data on
neurocognitive development of propranolol-treated infants
with IH is reassuring [12–15], further investigation of sleep
problems and other CNS effects was recommended in a recent
review article [6].
Current knowledge on sleep in propranolol-treated infants
is mainly based on studies that rely on parental perception of
infant’s sleep. Parent reports are a subjective quantification of
infant sleep quality, and agreement with objective sleep as-
sessment is poor [16, 17]. Furthermore, parents might be bi-
ased by their doctors and information leaflets mentioning
sleep problems as a side effect of propranolol therapy. As
infant sleep is highly variable and evolving over time, this
information might lead parents to interpret normal variability
of infant sleep as problematic [18].
Actigraphy is a convenient and cost-efficient method
allowing for the recording of sleep data over extended periods
in a natural environment, which may be particularly important
in infants [19]. Actigraphy has been shown to correlate well
with sleep data obtained from polysomnography [20, 21], and
its use has significantly increased in pediatric sleep research
over the last decades [22, 23]. Combination with a 24-h diary
markedly improves the capture of daytime sleep, which is an
integral part of total sleep duration in infancy[24].
In this cohort study, the sleep behavior of propranolol-
treated infants with IH was objectively investigated through
actigraphy and a 24-h diary at ages 3 and 6 months. In addi-




This cohort study consisted of a prospective cohort of infants
with propranolol treatment for IH, whose sleep behavior was
assessed over time, and a comparison with an identically de-
signed, historical cohort of untreated infants, whose sleep be-
havior was assessed in the same manner without any temporal
matching. The propranolol cohort consisted of otherwise
healthy infants treated with propranolol for a complicated
IH. The indication for treatment was made independently
from and prior to possible inclusion in this project. Infants
were recruited prospectively from the vascular anomalies
clinics of the University Children’s Hospital Zurich and the
Department of Pediatric Surgery, Charité University
Medicine, Berlin, from September 2018 through August
2020. The control group was composed of an equal number
of untreated matched healthy infants, investigated in an earlier
project on infant sleep using the same assessments and study
design [10, 24]. Matching criteria included subjects’ sex and
chronological age at both assessment timepoints at ages 3 and
6 months (maximum difference of equal or less than ± 10 days
at each timepoint). Inclusion criteria were healthy infants aged
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0–5.5 months at baseline, born at term (37–42 weeks of ges-
tation), and being mainly breastfed at time of inclusion (at
least 50% of daily nutrition intake) to match with the control
group [25]. Only vaginal birth was allowed in the control
cohort, whereas no restrictions regarding birth mode were
applied in the propranolol group. Exclusion criteria included
CNS disorders, acute illness, evidence of brain damage,
chronic pediatric disease, and a family background of narco-
lepsy or significant psychiatric disease. Low birth weight (<
2500 g), treatment with medications affecting the sleep-wake
cycle (apart from propranolol), and travelling across more
than one time zone less than 1 week prior to the measurements
also led to exclusion.
Propranolol treatment was performed according to current
guidelines [1, 26]. In case of intolerable side effects, patients
were offered off-label treatment with atenolol, a hydrophilic
cardio-selective beta-blocker (1 mg/kg/day, single daily dose)
[27].
Ethical approval was obtained according to local standards
(Cantonal ethics committee, BASEC 2018-01366, and 2016-
00730), and study procedures were consistent with the decla-
ration of Helsinki.Written parental consent was obtained in all
subjects before data collection.
Study procedures
Assessments were scheduled at ages 3 and 6 months, within a
1-month window centered around the target age. For subjects
initiating propranolol treatment after age 3 months, only one
assessment at 6 months was performed. In those infants who
stopped propranolol and were switched to atenolol, additional
measurements on atenolol were performed within the first 2
weeks after atenolol initiation.
Demographic data and patient characteristics were assessed
using patient charts and questionnaire data.
Sleep-wake behavior was quantified for 7–10 days at each
timepoint, simultaneously acquiring actigraphy and a 24-h
diary in the infant’s natural environment (usually at home).
GENEActiv movement sensors (Activinsights Ltd,
Kimbolton, UK, 43x40x13mm, MEMS sensor, 16 g, 30 Hz
Frequency recording resolution) were attached to the infant’s
left ankle in a modified sock (Fig. 1).
The 24-h diary was completed in 15-min resolution by
caregivers in parallel to the actigraphy recording. Diary data
included reporting on infant sleep, external movements occur-
ring during sleep (e.g., sleeping in a stroller/car), feeding ep-
isodes, propranolol administration, and bedtimes (clock time)
(Fig. 1).
Caregivers in both cohorts completed the Brief Infant Sleep
Questionnaire (BISQ) during the measurements, which is a
validated survey to assess infant sleep [28]. To investigate
the impact of the infants’ sleep behavior on the whole family,
both parents’ sleep quality was assessed using the Pittsburgh
Sleep Quality Index (PSQI) [29].
The behavioral development of infants in both cohorts was
investigated with the parent-completed age-appropriate Ages-
and-Stages questionnaire [30].
The Hemangioma Activity Score (HAS) was used to
document IH treatment response in the propranolol co-
hort [31].
Sleep analysis
Actigraphy data was processed according to in-laboratory
standards [10, 24]. A published algorithmwas applied to iden-
tify infant sleep and wake periods [19]. By applying a previ-
ously validated 6-step modification, a better fit with the 24-h
diary was achieved [24].
Primary outcomes
The primary outcomes were the objectively assessed Number
of Awakenings per hour of Night Sleep and Sleep Efficiency
(%), which is defined as the ratio of Total Sleep Time (at night)
and Sleep Opportunity (time spent in bed), at 3 and 6 months
[10]. Sleep Efficiency may be viewed as a marker for overall
nighttime sleep quality, as decreased values can correspond to
problems falling asleep, increased sleep fragmentation, early
waking up, or a combination thereof. These two variables
represent a sleep composite that we have previously reported
as Sleep Activity [10].
Secondary outcomes
Secondary objective sleep measures included 24-hour Total
Sleep and addressed the four remaining infant sleep compos-
ites, which we have previously identified as Sleep Night, Sleep
Day, Sleep Timing, and Sleep Variability [10]. Accordingly,
we selected the variables Sleep Period (time between Sleep
Onset and Sleep Offset at night in minutes, which represents
Sleep Night), Longest Wake (longest continuous wake period
during the day in minutes, which indirectly correlates with the
accumulation of daytime sleep need and thus Sleep Day),
Sleep Offset (morning wake time in hours, which represents
Sleep Timing), and Variability of Sleep Period (standard de-
viation of Sleep Period across measurement days (in minutes),
which represents Sleep Variability).
Secondary outcomes also encompassed subjective data ac-
cording to the parent-completed questionnaires, including da-
ta on infant sleep (24-hour Total Sleep, Number of Nighttime
Awakenings, Duration of Daytime Sleep, and Sleep
Problems), the parents’ sleep quality, and the behavioral de-
velopment at ages 3 and 6 months.
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Sample size calculation
Determination of the sample size was based on a two-sample
t-test power calculation with a two-sided significance level of
0.05 to give greater than or equal to 80% power to detect
differences of ≥25% in the Number of Nighttime
Awakenings in propranolol-treated infants versus controls at
6 months. This resulted in 44 required datasets per group.
Statistical analysis
Statistical analysis was done using R [32] and RStudio [33] and
the packages ggplot2, MASS, mosaic, kableExtra, pander,
lme4, lmerTest, cowplot, purr, qwraps2, psych, and dpylr
[34–39]. We compared the demographics of the control and
propranolol cohort by applying chi-square and t-tests. The ef-
ficacy of treatment (baseline, T1, and T2) was assessed using a
multilevel model (lmer), with varying intercepts for each pa-
tient. Differences in objective and subjective sleep variables, as
well as parental sleep quality and behavioral development,
were assessed using linear models with group (propranolol/
control) as predictors and exact age at measurement start, sex,
and gestational age at birth as control variables. Each timepoint
was analyzed separately, as we did not have complete datasets
for either timepoint, and not enough timepoints to utilize a
multilevel model. Alpha level was set to p < 0.05. Because
we included many objective and subjective sleep variables,
we controlled for multiple comparisons by applying a False
Discovery Rate (FDR) correction (Benjamini-Hochberg).
Results
Participants
Fifty-four subjects were included in each cohort (detailed pa-
tient characteristics are shown in Table 1). There were no
significant differences between cohorts except for a lower
gestational age in the propranolol group (mean, 39.3 vs.
40.0 weeks, p = 0.001). Thirty-four and 47 datasets were
Fig. 1 Methods used for
assessing objective sleep
measures. Attachment (a) of the
Actigraph (b) in a special sock on
the left ankle. Representative
example of a 24-hour diary (c)
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available to calculate objective sleep parameters at 3 and 6
months, respectively. For 7 participants, only 3-month assess-
ments were available due to treatment switch to atenolol be-
fore age 6 months (n = 2), vacation in the 6-month measure-
ment window (n = 1), loss to follow-up (n = 2), and withdraw-
al from the study (n = 2).
Treatment characteristics
A total of 70 IH were treated in 54 participants. The mean
propranolol dose was 1.9 mg/kg/day at both measurements,
and the mean duration of propranolol exposure at the begin-
ning of the measurements was 2.9 and 10.8 weeks at 3 and 6
months, respectively. For details on treatment, please refer to
Table 2. Therapy was highly effective, as evidenced by a
statistically significant decrease in the HAS across the study
period (p < 0.001, Fig. 2). No serious adverse events occurred.
Three patients (5.6%) were switched to atenolol at the age of 3
months (n = 2) and 6 months (n = 1), respectively, due to
intolerable sleep problems.
3-month objective sleep measures (actigraphy, 24-h
diary)
No differences in the objective sleep behavior were detected
between the two infant groups (all FDR corrected p-values >
0.05, Table 3). Boxplots displaying objective sleep measures
are shown in Fig. 3.
6-month objective sleep measures (actigraphy, 24-h
diary)
A significant reduction in infant Sleep Efficiency was de-
tected in the propranolol group (mean ±SD: 90.2 ± 5.0 %)
vs. the control group at age 6 months (92.1 ± 3.6 %; FDR
corrected p = 0.032). In concordance, the Number of
Awakenings per hour of Night Sleep was increased; this
was, however, not significant, when correcting for multi-
ple comparisons (FDR corrected p = 0.08). The Longest
Wake during the day was significantly shorter, by about
25 min, in treated infants (mean ±SD, 193.0 ± 28.3 min)
Table 1 Patient characteristics
Propranolol cohort (n = 54) Controls (n = 54) p = *
Gender
Male, n (%) 11 (20.4) 11 (20.4)
Female, n (%) 43 (79.6) 43 (79.6)
Gestational age at birth (weeks), mean ± SD (range) 39.3 ± 1.2 (37.0–42.0) 40.0 ± 1.0 (36.9–41.4) 0.001
Birth weight (grams), mean ± SD (range) 3371 ± 448 (2535–4150) 3373 ± 441 (2580–4600) 0.98
Birth mode < 0.001
Vaginal delivery, n (%) 35 (64.8) 54 (100)
Cesarean section, n (%) 14 (25.9) 0 (0)
Unknown, n (%) 5 (9.3) 0 (0)
Ethnicity 0.16
Caucasian, n 39 52
Hispanic, n 1 0
Mixed, n 7 2
Unknown, n 7 0
Age of the mother at inclusion (years), mean ± SD (range) 34.0 ± 4.1 (26.0–41.0) 34.1 ± 3.5 (25.0–42.0) 0.93
Age of the father at inclusion (years), mean ± SD (range) 35.7 ± 5.2 (27.0–46.0) 35.8 ± 4.9 (25.0–52.0) 0.90
Co-sleeping rate of infant and parents in the same bed
(% of total sleep time)
At age 3 months, mean ± SD 19.2 ± 28.1 28.9 ± 40.5 0.27
At age 6 months, mean ± SD 24.5 ± 32.7 25.1 ± 34.6 0.93
3-month assessments
Number of available recordings (male/female) 34 (8/26) 34 (8/26)
Mean age at initiation (months), mean ± SD (range) 2.9 ± 0.2 (2.4–3.2) 2.9 ± 0.2 (2.4–3.4) 0.80
6-month assessments
Number of available recordings (male/female) 47 (10/37) 47 (10/37)
Mean age at initiation (months), mean ± SD (range) 5.8 ± 0.3 (5.5–6.4) 5.8 ± 0.2 (5.5–6.2) 0.48
*Welch two-sample t-test/chi-square test
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Table 2 Propranolol treatment characteristics. IH infantile hemangioma
Total number of treated IH 70
IH location
Head/neck, n (%) 47 (67.1)
Trunk, n (%) 13 (18.6)
Extremities, n (%) 10 (14.3)
Reason for treatment
Life threatening IH, n (%) 0 (0)
Function threatening IH (%) 21 (38.9)
(Risk of) Ulceration (%) 14 (25.9)
Esthetic (%) 34 (63.0)
Age at propranolol initiation (months), mean ± SD (range) 3.2 ± 1.51 (1.1–6.3)
Propranolol dose (mg/kg/day), mean ± SD (range)
At initiation 2.0 ± 0.3 (0.8–3)
At 3 months 1.9 ± 0.4 (1–3)
At 6 months 1.9 ± 0.3 (1–3)
Duration of propranolol exposure at beginning of 3-month measurements (weeks), mean ± SD (range) 2.9 ± 1.9 (0–5.9)
Duration of propranolol exposure at beginning of 6-month measurements (weeks), mean ± SD (range) 10.8 ± 6.8 (0–20.1)
Hemangioma Activity Score (HAS)
At initiation ± SD (range) 4.4 ± 0.9 (2–6)
At 3 months ± SD (range) 3.3 ± 1.0 (1.3–5.5)
At 6 months ± SD (range) 2.2 ± 1.1 (0–5)
Serious adverse events, n (%) 0 (0)
Subjects switched to atenolol due to sleep disturbance, n (%) 3 (5.6)
Fig. 2 Treatment response of
infantile hemangiomas according
to the Hemangioma Activity
Score (HAS) showing a
statistically significant decrease


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































than controls (219.7 ± 33.5 min; FDR corrected p =
0.001), reflecting an increased demand for daytime sleep
in the propranolol group. No differences were evident in
the other objective sleep variables, including 24-h Total
Sleep (all FDR corrected p-values >0.05). All results are
shown in Table 3 and Fig. 3.
Subjective sleep measures (BISQ, PSQI)
No statistically significant differences occurred in the sub-
jective infant sleep parameters at 3 and 6 months, as dem-
onstrated in Table 3 and Fig. 4 (all FDR corrected p-
values > 0.05). About 15% and 30% of parents reported
sleep problems in both groups at age 3 and 6 months,
respectively. Nightmares (n = 2) and nighttime gastroin-
testinal complaints (n = 3) were only reported in the pro-
pranolol group at 6 months.
Parents’ sleep quality as assessed bymeans of the PSQI did
not differ between groups at either timepoint (p > 0.05).
Behavioral development (ASQ)
Scoring on the global age-appropriate Ages-and-Stages
Questionnaire did not differ between groups at both 3 and 6
months (p > 0.05). For details, see Table 3 and Fig. 4.
Atenolol treatment
Three patients (2 female/1 male) were switched from propran-
olol to atenolol therapy due to severe sleep problems. The
parents of these 3 infants complained about infants’ difficul-
ties falling asleep and nightly agitation, while one infant ad-
ditionally experienced nightmares/night terrors. In concor-
dance with these symptoms, all three patients had a relatively
low Sleep Efficiency with propranolol between 70.7 and
79.5% (Table 4, Fig. 5). Their families reported moderate to
considerable improvement of sleep after switching treatment.
The low number of subjects precluded statistical analysis.
However, descriptively, the Sleep Efficiency increased in all
three infants (increase ranged from +2.6 to 9.0%).
Additionally, the Longest Wake period during the day in-
creased by 8.7 to 30.3 min. 24-hour Total Sleep decreased
by 24.3 min and increased by 5.6 and 33.2 min in the three
infants, respectively.
Discussion
This is the largest study objectively assessing sleep in infants
treated with propranolol for IH. Our data show that propran-
olol exposure mainly affects infants’ nighttime sleep
Fig. 3 Boxplots of the main objective sleep measures. a Sleep Efficiency (%), bNumber of Awakenings per hour of Night Sleep, c 24-hour Total Sleep
(min), d Longest Wake (min). Sleep Efficiency and Longest Wake showed statistically significant differences between groups at age 6 months
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consolidation by reducing Sleep Efficiency and, at trend level,
increasing the Number of Nighttime Awakenings, compared to
untreated infants at age 6 months. This is clearly in line with
previous reports on sleep disturbance in propranolol-treated
infants [2, 4–7] and publications on adult patients reporting
increased nighttime awakenings, insomnia, and nightmares
while on propranolol and other beta-blockers [40–43].
However, infant 24-hour Total Sleep was not affected by
propranolol. This may suggest a compensatory mechanism,
such that decreased Sleep Efficiency at night is compensated
by increased napping during the day. This concept was indeed
evidenced by significantly reduced Longest Wake periods in
infants receiving propranolol.
While the reduction in Longest Wakemight be a mere catch-
up phenomenon, it could also be due to a direct influence of
propranolol on the CNS [3]. We have previously proposed that
Fig. 4 Main results of subjective sleep measures (BISQ) and assessment
of behavioral development (ASQ). a Number of Nighttime Awakenings,
b 24-hour Total Sleep (hours), c Frequency of sleep problems reported by
parents, d Scoring on the global ASQ assessing overall behavioral
development. No statistically significant differences were found in any
of these parameters. BISQ: Brief Infant Sleep Questionnaire. ASQ: Ages-
and-Stages Questionnaire
Table 4 Objective sleep measures in patients switched from propranolol to atenolol (n = 3)


















0.30 70.7 764.0 788.7 11.1 146.3 166.4
IHPS24 on atenolol 0.33 76.2 739.5 733 11.2 119.3 196.8
IHPS45 on propranolol
(age 3 months)
0.52 74.4 790.4 687.7 6.7 83.4 126.0
IHPS45 on atenolol 0.47 77.0 796.0 703 6.1 108.3 141.5
IHPS49 on propranolol
(age 6 months)
0.36 79.5 700.2 538.8 8.2 77.4 201.3
IHPS49 on atenolol 0.35 88.6 733.4 619.2 8.8 49.9 210.0
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daytime sleep and Longest Wake are markers of general matu-
ration in infancy, based on the observation that they are asso-
ciated with developmental outcomes of behavior [10].
In contrast to the observations at age 6 months, we did not
find any effects of propranolol on sleep behavior at age 3
months. Sleep behavior is continually evolving throughout
the first year of life and even beyond—a process of increasing
consolidation of the sleep-wake rhythm. Accordingly, Sleep
Efficiency is expected to be decreased at age 3 compared to
age 6 months, as was found in this study. Possible effects of
propranolol on Sleep Efficiencymight, therefore, be obscured.
Additionally, capturing sleep behavior using actigraphy is
more difficult in younger children, due to less vigorous move-
ments in waking phases. Finally, it may be possible that the
effects of propranolol on sleep might be increasing with lon-
ger exposure to the medication.
Interestingly, the subjective sleep measures in this study indi-
cated no differences in the infants’ and parents’ sleep quality
between groups, except for the occurrence of nightmares in 2
patients (5.1%) in the propranolol group at age 6 months.
These results are surprising as they contradict the objective find-
ings of this study and reports from the literature [2, 5], hence
supporting previous studies showing that agreement between
parent reports and objective sleep measurements is
insufficient[16, 17].
While sleep problems in infantsmay have immediate negative
effects on infant-parent bonding and lead to parental stress and
depression [44, 45], possible long-term adverse effects on the
infant’s behavioral development are of even greater importance
[44, 46]. A recent review article reported no significant
association of propranolol with CNS effects. However, there
seemed to be a trend for increased CNS effects of propranolol
compared to other non-corticosteroid treatments or placebo. Of
note, propranolol appeared to have a safer profile of CNS effects
than corticosteroids, the former mainstay treatment for IH [6].
Current data on behavioral development of children with
IH treated with propranolol in infancy are available up to age 7
years and very reassuring [12–15]. In line with this, we did not
detect any differences in the behavioral developmental scoring
on the Ages-and-Stages questionnaire between treated and
untreated children at 3 and 6 months.
Whereas the group differences in Sleep Efficiency and
Longest Wake were statistically significant at infant age 6
months, it may be debated whether these are clinically rele-
vant. If we assume an infant to spend 12 h in bed at night, the
mean difference of 1.9% in Sleep Efficiency between groups
corresponds to an absolute difference of ~14 min in total
nighttime sleep, which might be negligible. Taken together
with our findings of unaffected 24-hour Total Sleep, a com-
parable subjective sleep quality, and normal behavioral devel-
opment in both groups, we conclude that the impact of pro-
pranolol on the sleep behavior of infants, in general, is small.
Along these lines, a recent pilot study assessing sleep quality
in infants treated with propranolol based on the BISQ and
actigraphy in a small proportion of included children did not
find a significant impairment of sleep quality and pattern [47].
Nevertheless, a minority of infants seems particularly suscep-
tible to propranolol in terms of sleep, as evidenced by three
infants (5.6%) in our study requiring early treatment discontinu-
ation. These infants showed a low Sleep Efficiency on
Fig. 5 Plots showing the distribution of the objective sleep measurement
results of subjects in the propranolol group in relation to the full control
cohort (152 infants, percentiles) at 3 and 6months [10]. Blue dots indicate
subjects on propranolol; purple dots (n = 3) indicate subjects on
propranolol that had to be switched to atenolol later due to decreased
sleep quality. a Sleep Efficiency, b Longest Continuous Waking
Episode, c 24-hour Total Sleep
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propranolol, which improved when they were switched to aten-
olol. While the number of atenolol-treated infants in this study
was low, our findings are in keeping with previous reports sug-
gesting that infants with sleep problems on propranolol might
benefit from hydrophilic beta-blockers such as atenolol [27,
48]. Larger-scale studies targeting specifically the small sub-
group of infants whose sleep is affected by propranolol are re-
quired to understand why high susceptibility towards sleep dis-
turbances under propranolol can in rare cases occur.
How beta-blockers might influence sleep regulation is not yet
fully elucidated. Direct action on centrally located beta-adrener-
gic, noradrenergic, and serotonin receptors, suppression of night-
time melatonin secretion, and even indirect effects via nitric ox-
ide and hydrogen peroxide release have all been postulated [40,
49, 50]. Interestingly, melatonin supplementation was shown to
improve sleep in adults treated with beta-blockers [49].
Limitations
As IH are associatedwith preterm birth and low birth weight, a
significant proportion of propranolol-treated infants had to be
excluded [51]. Given the many confounders associated with
preterm infants’ sleep behavior (e.g., immature brain develop-
ment, respiratory problems, hospital admission in a neonatal
care unit), only term-born subjects were included in this study.
Therefore, we cannot exclude that effects of propranolol on
sleep behavior of (previously) preterm infants might be differ-
ent. In addition, we acknowledge that the usedmethodological
approach, notably the use of historical controls, may cause
secular biases and other potential distortion.
Conclusions
This is the largest study to examine with objective measures
whether propranolol treatment of infants with IH is linked to
altered sleep behavior. While propranolol therapy was associ-
ated with a reduction in Sleep Efficiency and an increase in
nighttime awakenings at age 6 months, 24-hour Total Sleep
did not differ between treatment and control groups. This ob-
servation suggests that infants compensate the effect of pro-
pranolol on nighttime sleep throughout the day. Future re-
search should address whether increased napping indeed
merely compensates for missed nighttime sleep—or whether
the altered daytime sleep in the propranolol group is indicative
of potential effects on the CNS and its maturation. No differ-
ences in parent-rated infants’ and parents’ subjective sleep
quality were detected, and infants on propranolol had normal
behavioral development at ages 3 and 6 months. The overall
impact of propranolol on infants’ sleep seemed mild.
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